meet celularity
Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ and tissue repair and functional regeneration. With this approach, our ambition is to augment human immunity and longevity, and to improve the human health span.
Backed by 100+ years of combined experience, our seasoned team of biopharmaceutical executives, scientists and clinicians has been integral to the success of numerous programs across discovery research, clinical development and commercialization in cancer immunotherapies and cell therapeutics. Everyone at Celularity is passionate about developing innovative treatment options that will make a meaningful difference in patients’ lives.
what makes celularity world class?
At Celularity, our vision is to be a world leading company accelerating commercial-scale cell therapeutics through our proprietary IMPACT™ platform, a transformative pillar in the treatment of cancer, inflammatory and age-related diseases.
our IMPACT™ platform
Our IMPACT™ (Immuno-Modulatory Placenta-derived Allogeneic Cell Therapy) platform is the foundation of a disruptive clinical development model that materially reduces time and cost to market for advanced cell therapies. Anchored by an expansive intellectual property estate, IMPACT™ includes novel Natural Killer (PNK) and cryopreserved PNK (CYNK) cells, along with genetically modified NK cells and allogeneic CAR-engineered placental T cells. Our demonstrated timeline from therapeutic discovery to Investigational New Drug (IND) application is less than 24 months.
Celularity’s integrated, highly scalable supply chain extends from sourcing biomaterials through advanced cell manufacturing, and our deep pipeline prioritizes hematological cancers and solid tumors, with longer term opportunities in diseases of aging.
CELULARITY IMPACT™ PLATFORM
our pipeline
cell therapy pipeline
LEADERSHIP TEAM
ROBERT J. HARIRI, MD, PHD
FOUNDER & CEO
Celgene, Weill Cornell Medicine
XIAOKUI ZHANG, PHD
EVP, CHIEF SCIENTIFIC OFFICER
Celgene, Rockefeller University
NASSIR HABBOUBI, MD
CHIEF MEDICAL OFFICER
Sanofi, Novartis
JOHN R. HAINES
EVP, CHIEF ADMINISTRATIVE OFFICER
Andiscern, Ionetix, University of Pennsylvania
DAVID C. BEERS
CHIEF FINANCIAL OFFICER
Goldman Sachs, T. Rowe Price
BETH STEINBRENNER
EVP, HUMAN RESOURCES
Celgene, Nabisco, Kraft Foods
BOARD OF DIRECTORS
JOHN SCULLEY
VICE CHAIR
Former CEO of Apple Inc; Former President of Pepsi-Cola
ANDREW C. VON ESCHENBACH, M.D.
BOARD MEMBER
Former Commissioner, United States FDA
PETER DIAMANDIS, M.D.
VICE CHAIR
Founder & Executive Chairman, XPRIZE; Executive Founder, Singularity University
ROBIN SMITH M.D., M.B.A.
BOARD MEMBER
Founder and Board Chair of Stem for Life Foundation; Founder and Board Chair of Cura Foundation
KOK-THAY LIM
BOARD MEMBER
Chairman and Chief Executive Officer, Genting Berhad
ANDREW PECORA, M.D., F.A.C.P., C.P.E.
BOARD MEMBER
Chief Innovation Officer, John Thereur Cancer Center
HENRI JI, Ph.D.
BOARD MEMBER
Co-Founder & CEO, Sorrento Therapeutics
JAISIM SHAH
BOARD MEMBER
Chief Executive Officer, Scilex Pharmaceuticals
newsroom
Celularity, Inc.
33 Technology Drive
Warren, NJ 07059
For Investor Inquiries: john.haines@celularity.com
For Media Inquiries: media@celularity.com